The breakthrough in glioblastoma – Oncopeptides on the new study data

On October 9, Oncopeptides presented exciting and important new data from its Insula study in glioblastoma – an aggressive form of brain cancer. The results show that the company’s drug candidate successfully crosses the challenging blood-brain barrier, reaches the tumor tissue as expected, and has so far been well tolerated by patients.

Successfully crossing the blood-brain barrier is a major milestone in cancer research, as no fewer than 90% of all drug candidates in this field fail at precisely this hurdle. What does this breakthrough actually mean for future treatments and for the company’s investors? How does the company’s PDC platform differ from today’s standard treatments, and what is the next step in the clinical development?

To explain the concepts, discuss the new analyses, and talk about the recently announced directed share issue, we are joined by Oncopeptides CEO Sofia Heigis and Chief Medical Officer Stefan Norin.

Podcast in Swedish only, follow this link for transcripts in Swedish and English:
https://oncopeptalks.com